XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information (Tables)
9 Months Ended
Oct. 01, 2021
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated
The following table presents sales by product line (in thousands):
 Three Months EndedNine Months Ended
October 1,
2021
October 2,
2020
October 1,
2021
October 2,
2020
Segment sales by product line:
Medical
Cardio & Vascular$160,858 $124,596 $462,632 $432,885 
Cardiac & Neuromodulation106,543 72,909 334,700 252,404 
Advanced Surgical, Orthopedics & Portable Medical28,720 30,179 83,380 92,041 
Total Medical296,121 227,684 880,712 777,330 
Non-Medical9,453 8,258 27,352 27,153 
Total sales$305,574 $235,942 $908,064 $804,483 
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following table presents income for the Company’s reportable segments (in thousands):
 Three Months EndedNine Months Ended
October 1,
2021
October 2,
2020
October 1,
2021
October 2,
2020
Segment income:
Medical$52,347 $28,777 $164,311 $120,903 
Non-Medical2,016 1,214 5,374 4,894 
Total segment income54,363 29,991 169,685 125,797 
Unallocated operating income (expenses)(a)
(21,273)9,767 (62,637)(32,778)
Operating income33,090 39,758 107,048 93,019 
Unallocated expenses, net(9,911)(8,358)(28,113)(24,815)
Income before taxes$23,179 $31,400 $78,935 $68,204 
__________
(a) Unallocated operating income (expenses) for the three and nine months ended October 2, 2020 includes a net gain of $28.2 million related to a patent litigation judgment.